Mark Juckett
Masonic Cancer Center, University of Minnesota · University of Wisconsin, Madison · Mayo Clinic
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mark Juckett as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:20 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05805605 · Allo HSCT Using RIC and PTCy for Hematological DiseasesMasonic Cancer Center, University of Minnesota · recruiting · Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia · principal investigator
- Ph2NCT01707004 · Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaUniversity of Wisconsin, Madison · completed · Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · principal investigator
- Ph2NCT00475150 · Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeNational Cancer Institute (NCI) · completed · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:20 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- BMT CTN Core - University of MinnesotaUG1HL069290 · NHLBI · UNIVERSITY OF MINNESOTA · fiscal years 2023 to 2026 · $232,500 awarded in 2026Same name and institution; not confirmed by an ID
- ZOSUQUIDAR TRIHYDROCHLORIDE IN NEWLY DIAGNOSED AMLM01RR003186 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · fiscal years 2006 · $3,414 awarded in 2006Same name and institution; not confirmed by an ID
- HEME & ENDOTHELIUM EFFECTS OF NITRIC OXIDE ON CATALYTIC IRONP41RR001008 · NCRR · MEDICAL COLLEGE OF WISCONSIN · fiscal years 1996 to 2000 · $11,274 awarded in 2000Same name and institution; not confirmed by an ID
- NITRIC OXIDE AND FERRITIN MEDIATED TUMOR CELL RESISTANCEK08CA068102 · NCI · MEDICAL COLLEGE OF WISCONSIN · fiscal years 1996 to 2000 · $49,130 awarded in 2000Same name and institution; not confirmed by an ID
- NITRIC OXIDE EFFECTS ON ENDOTHELIAL IRON KINETICSF32HL009289 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · fiscal years 1994 · $35,300 awarded in 1994Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- UW Comprehensive Cancer Center SupportP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · fiscal years 2018 to 2026Named on NCT01707004
- Pathology Research Shared ResourceP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI THOMAS J FLOTTE · fiscal years 2018 to 2026Named on NCT00475150
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in chronic myeloid leukemia.